During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:RGNX), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 4 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.11, a high estimate of $55.00, and a low estimate of $21.00. This current average reflects an increase of 7.25% from the previous average price target of $37.40.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain...
ログインすると全部閲覧できます。
ログイン